Mass. Biotech Clinches $92M Series A Funding Round
Massachusetts-based biotechnology company Triveni Bio Inc. on Thursday said it secured a series A funding round after raising $92 million from investors, which will be used to advance its lead antibody...To view the full article, register now.
Already a subscriber? Click here to view full article